LYR-210 for CRS
Our first product candidate targets chronic rhinosinusitis (CRS), which affects about 27 million - 11% of adults - in the U.S., and has no approved pharmaceutical treaments.
watch how lyr-210 works
Company news
Nov 26, 2019
Lyra Therapeutics To Present at the Evercore ISI 2nd Annual HealthCONx Conference
